Oxytocin

Oxytocin is a nine-amino-acid peptide with a loop closed by a sulphur bridge, made in the hypothalamus and released from the posterior pituitary. It was the first peptide hormone to have its structure determined and to be chemically synthesised, work that earned Vincent du Vigneaud the Nobel Prize in Chemistry in 1955 — it is one of the foundational molecules of peptide science.

Its classical functions are mechanical and beyond dispute: it causes the uterus to contract during labour and triggers the release of milk during feeding. Both are textbook physiology, both are clinically exploited, and neither is controversial.

Its second reputation, as a hormone of bonding and trust, is the one that made it famous and the one that requires care. Work in prairie voles — a species that forms lasting pair bonds, unlike its close relatives — established a genuine and important role in social behaviour. What followed was a wave of human studies that has since become one of the most cited cautionary tales in psychology about replication and over-interpretation.

• A foundational synthesis: Being the first peptide hormone synthesised chemically makes it a landmark in the field. The methods developed for it underlie how peptides are made today.

• Smooth muscle contraction: Its receptor triggers contraction in uterine and mammary smooth muscle through a well-mapped intracellular pathway. This is the part of its biology that is completely settled.

• Social behaviour in animals: Comparative work in voles linked receptor distribution in the brain to whether a species forms pair bonds. That is a strong, replicated finding about how receptor placement shapes behaviour.

• A replication problem worth studying: Human intranasal studies have replicated poorly, and the reasons — small samples, uncertain delivery to the brain, flexible analysis — are instructive about how a whole literature can be built on weak foundations.

The oxytocin receptor sits in the membrane of target cells and, when engaged, triggers a release of calcium inside them. In a muscle cell, calcium is the direct trigger for contraction — which is precisely what happens in the uterus during labour and in the tissue surrounding the milk ducts. This part of the mechanism is completely characterised.

In the brain the same receptor appears in regions concerned with reward, fear and social recognition, and this is where the story becomes more interesting and much less certain. The vole research showed that the difference between a species that pair-bonds and one that does not tracks where in the brain the receptors are, not how much hormone is present. Placement, not quantity — which is a subtle and important result.

The difficulty with human work is delivery. Oxytocin does not cross from blood into the brain readily, so studies administer it as a nasal spray on the assumption that some reaches the brain directly. How much does, and whether it arrives where it is needed, remains genuinely disputed. A large literature reporting effects on trust and empathy rests on that assumption, and the replication record of those studies has been poor.

Two separate answers are needed. On the classical functions the evidence is complete: structure, synthesis, receptor, mechanism and clinical use in obstetrics are all established and unambiguous.

Work on social and behavioural effects in humans has replicated poorly: effect sizes shrank as methods improved, and whether intranasal delivery reaches the brain is unresolved. It is supplied for laboratory research only. The animal work remains solid, and the comparative result — that receptor placement rather than hormone quantity tracks pair-bonding — is one of the more elegant findings in behavioural neuroscience.

Kisspeptin-10 is a useful comparison within neuroendocrinology: another peptide acting on hypothalamic circuits, but one whose role was established through human genetics rather than through behavioural inference — which is why its evidence is so much firmer.

PT-141 also acts centrally on behaviour-related circuits, through the melanocortin system, and unlike this one it completed clinical development.